{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T07:26:03Z","timestamp":1792740363353,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1016\/j.ejca.2010.08.019","type":"journal-article","created":{"date-parts":[[2010,9,21]],"date-time":"2010-09-21T04:44:21Z","timestamp":1285044261000},"page":"277-286","source":"Crossref","is-referenced-by-count":43,"title":["Sorafenib tosylate and paclitaxel induce anti-angiogenic, anti-tumour and anti-resorptive effects in experimental breast cancer bone metastases"],"prefix":"10.1016","volume":"47","author":[{"given":"Maximilian","family":"Merz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorde","family":"Komljenovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Zwick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfhard","family":"Semmler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"B\u00e4uerle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ejca.2010.08.019_b0005","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0959-8049(99)00331-7","article-title":"Risk of complications from bone metastases in breast cancer. Implications for management","volume":"36","author":"Plunkett","year":"2000","journal-title":"Eur J Cancer"},{"issue":"20 Pt 2","key":"10.1016\/j.ejca.2010.08.019_b0150","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"20 Pt 2","key":"10.1016\/j.ejca.2010.08.019_b0155","doi-asserted-by":"crossref","first-page":"6258s","DOI":"10.1158\/1078-0432.CCR-06-0840","article-title":"Breast cancer: bisphosphonate therapy for metastatic bone disease","volume":"12","author":"Body","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"6 Suppl 16","key":"10.1016\/j.ejca.2010.08.019_b0160","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/sonc.2002.37263","article-title":"Role of angiogenesis in tumor growth and metastasis","volume":"29","author":"Folkman","year":"2002","journal-title":"Semin Oncol"},{"issue":"26","key":"10.1016\/j.ejca.2010.08.019_b0025","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1056\/NEJM199512283332608","article-title":"Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis","volume":"333","author":"Folkman","year":"1995","journal-title":"New Engl J Med"},{"issue":"9","key":"10.1016\/j.ejca.2010.08.019_b0030","doi-asserted-by":"crossref","first-page":"e6896","DOI":"10.1371\/journal.pone.0006896","article-title":"Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment","volume":"4","author":"Dunn","year":"2009","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.ejca.2010.08.019_b0035","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0014-5793(00)01520-9","article-title":"Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts","volume":"473","author":"Nakagawa","year":"2000","journal-title":"FEBS Lett"},{"issue":"5","key":"10.1016\/j.ejca.2010.08.019_b0040","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1593\/neo.08220","article-title":"Bevacizumab inhibits breast cancer-induced osteolysis, surrounding soft tissue metastasis, and angiogenesis in rats as visualized by VCT and MRI","volume":"10","author":"B\u00e4uerle","year":"2008","journal-title":"Neoplasia"},{"issue":"12","key":"10.1016\/j.ejca.2010.08.019_b0045","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1158\/1078-0432.CCR-09-2932","article-title":"Drug induced vessel remodeling in bone metastases as assessed by dynamic contrast enhanced MRI and vessel size imaging \u2013 a longitudinal in vivo study","volume":"16","author":"B\u00e4uerle","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.ejca.2010.08.019_b0050","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/nrd2130","article-title":"Discovery and development of sorafenib: a multikinase inhibitor for treating cancer","volume":"5","author":"Wilhelm","year":"2006","journal-title":"Nat Rev Drug Discov"},{"issue":"19","key":"10.1016\/j.ejca.2010.08.019_b0055","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.ejca.2010.08.019_b0060","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nrclinonc.2009.63","article-title":"Biomarkers of response and resistance to antiangiogenic therapy","volume":"6","author":"Jain","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2010.08.019_b0065","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/1522-2594(200103)45:3<397::AID-MRM1052>3.0.CO;2-3","article-title":"Vessel size imaging","volume":"45","author":"Tropres","year":"2001","journal-title":"Magn Reson Med"},{"issue":"5","key":"10.1016\/j.ejca.2010.08.019_b0070","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/jmri.21710","article-title":"Assessment of vascular remodeling under antiangiogenic therapy using DCE-MRI and vessel size imaging","volume":"29","author":"Zwick","year":"2009","journal-title":"J Magn Reson Imaging"},{"issue":"8","key":"10.1016\/j.ejca.2010.08.019_b0075","doi-asserted-by":"crossref","first-page":"3524","DOI":"10.1158\/0008-5472.CAN-06-4236","article-title":"An imaging biomarker of early treatment response in prostate cancer that has metastasized to the bone","volume":"67","author":"Lee","year":"2007","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.ejca.2010.08.019_b0080","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/ijc.20840","article-title":"Characterization of a rat model with site-specific bone metastasis induced by MDA-MB-231 breast cancer cells and its application to the effects of an antibody against bone sialoprotein","volume":"115","author":"B\u00e4uerle","year":"2005","journal-title":"Int J Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2010.08.019_b0085","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/00004728-199107000-00018","article-title":"Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging","volume":"15","author":"Brix","year":"1991","journal-title":"J Comput Assist Tomogr"},{"issue":"3","key":"10.1016\/j.ejca.2010.08.019_b0090","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S0720-048X(02)00310-8","article-title":"Apparent diffusion coefficient: a quantitative parameter for in vivo tumor characterization","volume":"45","author":"Herneth","year":"2003","journal-title":"Eur J Radiol"},{"issue":"8","key":"10.1016\/j.ejca.2010.08.019_b0095","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1007\/s00330-006-0566-x","article-title":"Non-invasive assessment of vessel morphology and function in tumors by magnetic resonance imaging","volume":"17","author":"Kiessling","year":"2007","journal-title":"Eur Radiol"},{"issue":"2","key":"10.1016\/j.ejca.2010.08.019_b0100","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1172\/JCI5028","article-title":"Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal","volume":"103","author":"Benjamin","year":"1999","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.ejca.2010.08.019_b0105","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2353\/ajpath.2009.080627","article-title":"A physical mechanism for coupling bone resorption and formation in adult human bone","volume":"174","author":"Andersen","year":"2009","journal-title":"Am J Pathol"},{"issue":"4","key":"10.1016\/j.ejca.2010.08.019_b0110","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1359\/jbmr.1998.13.4.581","article-title":"Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras","volume":"13","author":"Luckman","year":"1998","journal-title":"J Bone Miner Res"},{"issue":"19","key":"10.1016\/j.ejca.2010.08.019_b0115","doi-asserted-by":"crossref","first-page":"9346","DOI":"10.1158\/0008-5472.CAN-06-4508","article-title":"The activity of zoledronic acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation","volume":"67","author":"Peng","year":"2007","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.ejca.2010.08.019_b0120","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1158\/1078-0432.CCR-08-3123","article-title":"Sagopilone inhibits breast cancer bone metastasis and bone destruction due to simultaneous inhibition of both tumor growth and bone resorption","volume":"15","author":"Strube","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.ejca.2010.08.019_b0125","first-page":"1843","article-title":"The microtubule-affecting drug paclitaxel has antiangiogenic activity","volume":"2","author":"Belotti","year":"1996","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.ejca.2010.08.019_b0130","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1158\/1078-0432.CCR-08-2710","article-title":"Antivascular actions of microtubule-binding drugs","volume":"15","author":"Schwartz","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"26","key":"10.1016\/j.ejca.2010.08.019_b0135","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"New Engl J Med"},{"issue":"6","key":"10.1016\/j.ejca.2010.08.019_b0140","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1158\/1078-0432.CCR-05-1615","article-title":"The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis","volume":"12","author":"Naumova","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"5706","key":"10.1016\/j.ejca.2010.08.019_b0145","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1126\/science.1104819","article-title":"Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy","volume":"307","author":"Jain","year":"2005","journal-title":"Science"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804910008427?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804910008427?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,7]],"date-time":"2018-12-07T18:55:47Z","timestamp":1544208947000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804910008427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["S0959804910008427"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2010.08.019","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1]]}}}